These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10762139)

  • 41. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms compensating for dopamine loss in early Parkinson disease.
    Brotchie J; Fitzer-Attas C
    Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents.
    Massart R; Guilloux JP; Mignon V; Sokoloff P; Diaz J
    Eur J Neurosci; 2009 Aug; 30(3):397-414. PubMed ID: 19656174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
    Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
    J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 50. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
    J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
    J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Striatal NMDA receptors gate cortico-pallidal synchronization in a rat model of Parkinson's disease.
    Zold CL; Escande MV; Pomata PE; Riquelme LA; Murer MG
    Neurobiol Dis; 2012 Jul; 47(1):38-48. PubMed ID: 22465187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of Striatal N-Methyl-D-Aspartate Receptor (NMDAR) Function by Phosphorylation of its Subunits in Parkinsonian Rats.
    Oh JD
    Methods Mol Med; 2001; 62():247-53. PubMed ID: 21318780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
    Oh JD; Geller AI; Zhang Gr; Chase TN
    Brain Res; 2003 May; 971(1):18-30. PubMed ID: 12691833
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
    Blanchet PJ; Papa SM; Metman LV; Mouradian MM; Chase TN
    Neurosci Biobehav Rev; 1997 Jul; 21(4):447-53. PubMed ID: 9195602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Behavioural pharmacology of glutamate in the basal ganglia.
    Schmidt WJ; Bubser M; Hauber W
    J Neural Transm Suppl; 1992; 38():65-89. PubMed ID: 1491249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Striatal glutamatergic mechanisms and extrapyramidal movement disorders.
    Chase TN; Bibbiani F; Oh JD
    Neurotox Res; 2003; 5(1-2):139-46. PubMed ID: 12832228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis.
    Di Chiara G; Morelli M
    Adv Neurol; 1993; 60():102-6. PubMed ID: 8093571
    [No Abstract]   [Full Text] [Related]  

  • 60. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
    Di Rocco A; Werner P
    Ann Neurol; 2000 Jan; 47(1):136-7. PubMed ID: 10632116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.